Printer Friendly

LAIS EXPANDS INTERNATIONAL MARKETING EFFORT

 LAIS EXPANDS INTERNATIONAL MARKETING EFFORT
 IRVINE, Calif., Aug. 4 /PRNewswire/ -- Advanced Interventional


Systems (NASDAQ: LAIS) today announced that it will expand its sales and marketing efforts to take increased advantage of sales opportunities for its excimer laser angioplasty system in international markets.
 Since January 1992, when LAIS' excimer laser device was approved by the Federal Food and Drug Administration for treating blocked arteries in the heart, the company has focused primarily on gearing up its sales and marketing efforts domestically, according to Robert E. Wall, LAIS' chairman and chief executive officer.
 "The international community, in addition to the market in the United States, also represents an important opportunity for LAIS. We have asked Richard Paige, formerly the company's vice president of marketing, to assume specific responsibility for directing the effort to increase our sales in the international marketplace," Wall said.
 Previously, Paige's marketing responsibilities were divided between both the domestic and international markets. Tom Allen, currently president and chief operating officer, will assume responsibility for directing the sales and marketing efforts in the United States. Allen has had a successful background in building substantial sales and marketing departments at both Marquette Electronics Inc. and Baxter Healthcare Edwards Division.
 "Mr. Paige, who joined LAIS in December 1991, has significant experience in international sales. We believe a more concentrated effort internationally will have a significant impact on the company's ability to penetrate our targeted overseas accounts," Wall said.
 "Having treated over 4,000 patients worldwide with an overall 90 percent success rate, LAIS continues to demonstrate that excimer laser coronary angioplasty performed with the Dymer 200+ system provides a significant clinical alternative for patients who do not do well with balloon angioplasty. Our most important ongoing challenge is to continue to educate interventional cardiologists worldwide about the demonstrated clinical benefit of laser angioplasty. It is a procedure that provides an important alternative for treating patients with complex cases of heart disease that previously would have required bypass surgery," he said.
 LAIS pioneered excimer laser angioplasty and is the technological leader in the development of laser systems for cardiovascular applications. The company was founded in 1986 and completed its initial public offering in November 1991. On Jan. 31, 1992, it became the first company to receive approval from the FDA to market a laser angioplasty system designed to treat heart disease.
 -0- 8/4/92
 /CONTACT: Connie McCluskey of Advanced Interventional Systems, 714-586-1342 or 714-581-8510, ext. 234/
 (LAIS) CO: Advanced Interventional Systems ST: California IN: MTC SU:


JB-AL -- LA037 -- 6883 08/04/92 19:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 4, 1992
Words:423
Previous Article:I.S.G. TECHNOLOGIES INC. ANNOUNCES RECORD REVENUES AND EARNINGS
Next Article:MORNINGSTAR GROUP REPORTS IMPROVED RESULTS FROM REMAINING OPERATIONS; INITIATES CASH DIVIDEND ON COMMON STOCK
Topics:


Related Articles
LAIS TAKES ACTION IN PATENT DISPUTE
ADVANCED INTERVENTIONAL SYSTEMS ANNOUNCES SECOND QUARTER RESULTS
LAIS DOWNSIZES DUE TO SLOWER THAN EXPECTED GROWTH; NINE MONTH REVENUES INCREASE FROM SAME PERIOD IN 1991, BUT ARE BELOW EXPECTATIONS
LAIS COMPLETES CORPORATE RESTRUCTURING EFFORTS
DISTRICT COURT ISSUES INJUNCTION IN PATENT DISPUTE
ADVANCED INTERVENTIONAL SYSTEMS REPORTS 1993 FIRST QUARTER RESULTS
ADVANCED INTERVENTIONAL SYSTEMS RECEIVES MARKETING APPROVAL FOR TWO OF ITS 50-MICRON FIBEROPTIC-BASED CATHETERS
ADVANCED INTERVENTIONAL SYSTEMS INC.WILL EVALUATE SPECTRANETICS PROPOSAL
ADVANCED INTERVENTIONAL SYSTEMS REJECTS SPECTRANETICS PROPOSAL
ADVANCED INTERVENTIONAL SYSTEMS REPORTS FIRST QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters